Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 485

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Open access
Thompson, Mark G., Burgess, Jefferey L., Naleway, Allison L., Tyner, Harmony, Yoon, Sarang K., Meece, Jennifer, Olsho, Lauren E.W., Caban-Martinez, Alberto J., Fowlkes, Ashley L., Lutrick, Karen, Groom, Holly C., Dunnigan, Kayan, Odean, Marilyn J., Hegmann, Kurt, Stefanski, Elisha, Edwards, Laura J., Schaefer-Solle, Natasha, Grant, Lauren, Ellingson, Katherine, Kuntz, Jennifer L., Zunie, Tnelda, Thiese, Matthew S., Ivacic, Lynn, Wesley, Meredith G., Mayo Lamberte, Julie, Sun, Xiaoxiao, Smith, Michael E., Phillips, Andrew L., Groover, Kimberly D., Yoo, Young M., Gerald, Joseph, Brown, Rachel T., Herring, Meghan K., Joseph, Gregory, Beitel, Shawn, Morrill, Tyler C., Mak, Josephine, Rivers, Patrick, Poe, Brandon P., Lynch, Brian, Zhou, Yingtao, Zhang, Jing, Kelleher, Anna, Li, Yan, Dickerson, Monica, Hanson, Erika, Guenther, Kyley, Tong, Suxiang, Bateman, Allen, Reisdorf, Erik, Barnes, John, Azziz-Baumgartner, Eduardo, Hunt, Danielle R., Arvay, Melissa L., Kutty, Preeta, Fry, Alicia M., Gaglani, Manjusha·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2107058
Open this paper in CoChat — free account

Abstract

BACKGROUND: Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions. METHODS: We conducted a prospective cohort study involving 3975 health care personnel, first responders, and other essential and frontline workers. From December 14, 2020, to April 10, 2021, the participants completed weekly SARS-CoV-2 testing by providing mid-turbinate nasal swabs for qualitative and quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) analysis. The formula for calculating vaccine effectiveness was 100% × (1 - hazard ratio for SARS-CoV-2 infection in vaccinated vs. unvaccinated participants), with adjustments for the propensity to be vaccinated, study site, occupation, and local viral circulation. RESULTS: SARS-CoV-2 was detected in 204 participants (5%), of whom 5 were fully vaccinated (≥14 days after dose 2), 11 partially vaccinated (≥14 days after dose 1 and <14 days after dose 2), and 156 unvaccinated; the 32 participants with indeterminate vaccination status (<14 days after dose 1) were excluded. Adjusted vaccine effectiveness was 91% (95% confidence interval [CI], 76 to 97) with full vaccination and 81% (95% CI, 64 to 90) with partial vaccination. Among participants with SARS-CoV-2 infection, the mean viral RNA load was 40% lower (95% CI, 16 to 57) in partially or fully vaccinated participants than in unvaccinated participants. In addition, the risk of febrile symptoms was 58% lower (relative risk, 0.42; 95% CI, 0.18 to 0.98) and the duration of illness was shorter, with 2.3 fewer days spent sick in bed (95% CI, 0.8 to 3.7). CONCLUSIONS: Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines attenuated the viral RNA load, risk of febrile symptoms, and duration of illness among those who had breakthrough infection despite vaccination. (Funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107058

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 485

Metadata

Authors
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., Groom, H. C., Dunnigan, K., Odean, M. J., Hegmann, K., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., Kuntz, J. L., Zunie, T., Thiese, M. S., Ivacic, L., Wesley, M. G., Mayo Lamberte, J., Sun, X., Smith, M. E., Phillips, A. L., Groover, K. D., Yoo, Y. M., Gerald, J., Brown, R. T., Herring, M. K., Joseph, G., Beitel, S., Morrill, T. C., Mak, J., Rivers, P., Poe, B. P., Lynch, B., Zhou, Y., Zhang, J., Kelleher, A., Li, Y., Dickerson, M., Hanson, E., Guenther, K., Tong, S., Bateman, A., Reisdorf, E., Barnes, J., Azziz-Baumgartner, E., Hunt, D. R., Arvay, M. L., Kutty, P., Fry, A. M., & Gaglani, M.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2021-07-22
Volume
385
Issue
4
Pages
320-329
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2107058
OpenAlex
W3176239731
Cited by
485
References
23
FWCI
32.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. https://app.cochat.ai/papers/10.1056/nejmoa2107058
The paper
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., Groom, H. C., Dunnigan, K., Odean, M. J., Hegmann, K., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2107058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.